Prostate Cancer Detection Using the Stockholm3 Test and MR/Fusion Biopsies (STHLM3MR-2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03377881|
Recruitment Status : Completed
First Posted : December 19, 2017
Last Update Posted : December 14, 2020
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Procedure: MRI/Fusion biopsies Procedure: Systematic biopsies||Not Applicable|
The overarching strategy of the STHLM3-MR/Fusion projects are to study an improved diagnostic pipeline including an improved blood-based test for identification of men with increased risk of prostate cancer and use of MRI to select men for diagnostic workup with targeted prostate biopsies. The aim is to increase the specificity in early detection of prostate cancer without decreasing the sensitivity of aggressive prostate cancers.
The primary endpoints are the number of performed biopsies, the number of performed MRI and the number of detected high-risk prostate cancers. Secondary endpoints include the number of low risk prostate cancers diagnosed and the proportion of patients with up-or downgraded disease after assessment of prostatectomy specimen. Additional aims include to assess the health economic consequences and development of automated image-analysis.
The STHLM3-MR project is performed in two separate phases, analyzed separately. STHLM3-MR Phase 1 closed inclusion 2017-06-01. All participants underwent target and systematic biopsies together with STHLM3 test analysis. The study is constitutes a current practice cohort and levels of the STHLM3 test were not used for selecting participants.
STHLM3-MR Phase 2 is a study comparing traditional prostate cancer detection using PSA and systematic biopsies with the improved pipeline for prostate cancer detection using the STHLM3 test and targeted biopsies in a screening context.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12750 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Two-step design with a first step using paired design for blood-analysis and a second step using randomisation between prostate biopsy strategy.|
|Masking:||None (Open Label)|
|Official Title:||STHLM3 MR Phase 2: A New Diagnostic Chain for Prostate Cancer Detection Using the Stockholm3 Test and MR/Fusion Biopsies|
|Actual Study Start Date :||April 4, 2018|
|Actual Primary Completion Date :||December 10, 2020|
|Actual Study Completion Date :||December 10, 2020|
The traditional/control arm consists of PSA testing and if PSA>3ng/ml a systematic biopsy of the prostate is performed.
Procedure: Systematic biopsies
The intervention in the control arm is traditional systematic biopsies of the prostate.
The experimental arm consists of a Stockholm3 bloodiest and if elevated, an MRI is recommended with targeted biopsies to prostate lesions.
Procedure: MRI/Fusion biopsies
The intervention in the experimental arm is an MRI with targeted biopsies using fusion technique to prostate lesions.
- Number of detected cancers characterized as Gleason Score ≥7 on evaluation of biopsy specimen [ Time Frame: At 2 months after study closure (last included biopsy procedure) ]Cancers detected by pathological evaluation of biopsy specimen collected from the respective study arm
- Number of detected cancer with Gleason Score 6 [ Time Frame: At 2 months after study closure (last included biopsy procedure) ]Cancers detected by pathological evaluation of biopsy specimen collected from the respective study arm
- Number of performed biopsy procedures in the study arms [ Time Frame: At 2 months after study closure (last included biopsy procedure) ]Number of performed prostate biopsy procedures counted per study arm
- Number of performed MRI in the study arms [ Time Frame: At 2 months after study closure (last included biopsy procedure) ]Number of performed prostate MRI procedures counted per study arm
- Number of infectious complications [ Time Frame: Questionnaire collection finalised within 2months after last biopsy procedure in study ]As assessed by questionnaire within 2 month after biopsy procedure
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03377881
|Capio St Görans Hospital|
|GHP Odenplan Urology|
|Principal Investigator:||Tobias Nordström, MD PhD||Karolinska Institutet|